COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
2.931
+0.021 (0.72%)
Nov 22, 2024, 4:00 PM EST - Market closed
COSCIENS Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 20 | 34.02 | 50.61 | 65.3 | 24.27 | 7.84 | Upgrade
|
Cash & Short-Term Investments | 20 | 34.02 | 50.61 | 65.3 | 24.27 | 7.84 | Upgrade
|
Cash Growth | -48.40% | -32.79% | -22.49% | 169.05% | 209.66% | -45.99% | Upgrade
|
Accounts Receivable | 1.89 | 0.07 | 0.4 | 0.88 | 1.19 | 0.21 | Upgrade
|
Other Receivables | 0.12 | 0.28 | 1.76 | 2.8 | 1.09 | 0.45 | Upgrade
|
Receivables | 2.02 | 0.34 | 2.16 | 3.68 | 2.28 | 0.66 | Upgrade
|
Inventory | 3.31 | 0.07 | 0.23 | 0.07 | 0.02 | 1.38 | Upgrade
|
Prepaid Expenses | 1.95 | 0.25 | 0.43 | 0.42 | 1.02 | 0.79 | Upgrade
|
Other Current Assets | 0.96 | 1.69 | 2.06 | 1.35 | 0.02 | 0.25 | Upgrade
|
Total Current Assets | 28.22 | 36.37 | 55.49 | 70.82 | 27.61 | 10.91 | Upgrade
|
Property, Plant & Equipment | 11.81 | 0.32 | 0.22 | 0.19 | 0.18 | 0.62 | Upgrade
|
Goodwill | - | - | - | 8.13 | 8.82 | 8.05 | Upgrade
|
Other Intangible Assets | 1.81 | - | - | 0.63 | 0.06 | 0.04 | Upgrade
|
Long-Term Deferred Tax Assets | 1.08 | - | - | - | - | - | Upgrade
|
Other Long-Term Assets | 0.86 | 0.33 | 0.32 | 0.34 | 0.34 | 0.36 | Upgrade
|
Total Assets | 43.77 | 37.02 | 56.03 | 80.1 | 37.01 | 19.98 | Upgrade
|
Accounts Payable | 2.4 | 1.87 | 2.04 | 0.93 | 1.19 | 1.09 | Upgrade
|
Accrued Expenses | 2.56 | 1.76 | 1.79 | 1.74 | 1.01 | 1.06 | Upgrade
|
Short-Term Debt | - | - | - | - | - | 0 | Upgrade
|
Current Portion of Leases | 0.41 | 0.16 | 0.11 | 0.13 | 0.14 | 0.65 | Upgrade
|
Current Income Taxes Payable | 0.11 | 0.11 | 0.11 | 0.12 | 0.12 | 1.45 | Upgrade
|
Current Unearned Revenue | 0.05 | 0.22 | 2.95 | 4.82 | 2.19 | 0.99 | Upgrade
|
Other Current Liabilities | 2.65 | 0.43 | 0.05 | 0.03 | 0.09 | 0.42 | Upgrade
|
Total Current Liabilities | 8.17 | 4.54 | 7.04 | 7.77 | 4.74 | 5.66 | Upgrade
|
Long-Term Leases | 1.21 | 0.12 | 0.07 | 0.03 | 0.05 | 0.26 | Upgrade
|
Long-Term Unearned Revenue | 1.92 | 1.54 | 1.79 | 1.59 | 3.29 | 0.19 | Upgrade
|
Other Long-Term Liabilities | - | - | 0.19 | 0.24 | 0.28 | 2.56 | Upgrade
|
Total Liabilities | 23.76 | 18.82 | 20.25 | 27.12 | 23.79 | 22.44 | Upgrade
|
Common Stock | 22.39 | 293.41 | 293.41 | 293.41 | 235.01 | 224.53 | Upgrade
|
Additional Paid-In Capital | - | 90.71 | 90.33 | - | - | - | Upgrade
|
Retained Earnings | -5.16 | -369.83 | -352.08 | -334.62 | -322.66 | -316.89 | Upgrade
|
Comprehensive Income & Other | 2.78 | 3.91 | 4.12 | 94.2 | 100.86 | 89.9 | Upgrade
|
Shareholders' Equity | 20.01 | 18.2 | 35.78 | 52.99 | 13.21 | -2.46 | Upgrade
|
Total Liabilities & Equity | 43.77 | 37.02 | 56.03 | 80.1 | 37.01 | 19.98 | Upgrade
|
Total Debt | 1.62 | 0.28 | 0.18 | 0.16 | 0.18 | 0.91 | Upgrade
|
Net Cash (Debt) | 18.38 | 33.74 | 50.43 | 65.14 | 24.09 | 6.93 | Upgrade
|
Net Cash Growth | -52.30% | -33.10% | -22.58% | 170.43% | 247.53% | -49.68% | Upgrade
|
Net Cash Per Share | 11.31 | 27.79 | 41.54 | 56.68 | 58.63 | 39.62 | Upgrade
|
Filing Date Shares Outstanding | 3.12 | 1.21 | 1.21 | 1.21 | 1.21 | 0.23 | Upgrade
|
Total Common Shares Outstanding | 3.12 | 1.21 | 1.21 | 1.21 | 0.63 | 0.2 | Upgrade
|
Working Capital | 20.05 | 31.83 | 48.44 | 63.05 | 22.87 | 5.25 | Upgrade
|
Book Value Per Share | 6.41 | 14.99 | 29.47 | 43.65 | 21.08 | -12.32 | Upgrade
|
Tangible Book Value | 18.21 | 18.2 | 35.78 | 44.23 | 4.34 | -10.55 | Upgrade
|
Tangible Book Value Per Share | 5.83 | 14.99 | 29.47 | 36.44 | 6.92 | -52.78 | Upgrade
|
Machinery | 13.16 | 0.49 | 0.45 | 0.47 | 0.55 | 0.74 | Upgrade
|
Leasehold Improvements | 6.57 | - | - | - | - | 0.03 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.